Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Bruton tyrosine kinase (Btk) is crucial for B-cell activation and myeloid cell signaling.
• Btk inhibitors have shown potential in preventing lupus.
• End-organ inflammation is a significant complication in systemic rheumatic diseases.

Purpose of the Study:

• To evaluate the efficacy of a Btk inhibitor (BTKB66) in preclinical models of end-organ inflammation.
• To investigate the therapeutic and preventative effects of BTKB66 in lupus nephritis, anti-GBM nephritis, and bleomycin-induced systemic sclerosis (SSc)-like skin and lung disease.

Main Methods:

• Treatment with BTKB66 in BWF1 lupus nephritis mice, anti-GBM nephritis models, and bleomycin-induced SSc-like skin and lung disease models.
• Assessment of renal damage (functional and histological), proteinuria, skin thickness, fibrosis, collagen deposition, inflammation, and lung inflammatory cell infiltration.
• Analysis of immune cell populations, including macrophages and T-cells.

Main Results:

• BTKB66 treatment reduced renal damage and proteinuria in lupus nephritis.
• BTKB66 effectively blocked renal disease in anti-GBM nephritis, comparable to dexamethasone.
• BTKB66 demonstrated therapeutic and preventative effects in bleomycin-induced SSc-like disease, reducing skin and lung pathology.
• Therapeutic benefits were linked to reduced numbers of macrophages and activated T-cells.

Conclusions:

• Btk inhibition, specifically with BTKB66, is effective in treating multiple models of end-organ inflammation.
• BTKB66 shows promise as a therapeutic agent for systemic rheumatic diseases affecting organs like the kidneys, skin, and lungs.
• Targeting Btk may offer a novel strategy for managing patients with complex systemic rheumatic conditions.